---
layout: default
title: Dronedarone
description: "Dronedarone çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚é«˜è­‰æ“šç­‰ç´š L2ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: é«˜è­‰æ“šç­‰ç´š (L1-L2)
nav_order: 63
evidence_level: L2
indication_count: 10
---

# Dronedarone

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L2</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Dronedaroneï¼šå¾å¿ƒæˆ¿çº–ç¶­é¡«å‹•åˆ°ä¸­é¢¨ç–¾ç—…

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Dronedarone å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Dronedarone åŸæœ¬ç”¨æ–¼æ²»ç™‚é™£ç™¼æ€§æˆ–æŒçºŒæ€§å¿ƒæˆ¿çº–ç¶­é¡«å‹•/å¿ƒæˆ¿æ’²å‹•ã€‚
TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**ä¸­é¢¨ç–¾ç—… (stroke disorder)** æœ‰æ•ˆï¼Œ
ç›®å‰æœ‰ **å¤šå€‹è‡¨åºŠè©¦é©—**å’Œ **å¤šç¯‡æ–‡ç»**æ”¯æŒé€™å€‹æ–¹å‘ã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | å¿ƒæˆ¿çº–ç¶­é¡«å‹•ã€å¿ƒæˆ¿æ’²å‹• |
| é æ¸¬æ–°é©æ‡‰ç—‡ | stroke disorderã€obsolete susceptibility to ischemic strokeã€ABri amyloidosisã€cerebrovascular disorderã€brain stem infarctionã€atrial fibrillation (disease)ã€sick sinus syndrome 2, autosomal dominantã€duodenal obstructionã€cerebral artery occlusionã€sarcoglycanopathy |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.97% |
| è­‰æ“šç­‰ç´š | L2 |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 1 å¼µ |
| å»ºè­°æ±ºç­– | Proceed with Guardrails |


## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. stroke disorder</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.97%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content" markdown="1">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

<p class="key-answer" data-question="é€™å€‹è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰æ˜¯ä»€éº¼ï¼Ÿ">
Dronedarone æ˜¯ amiodarone çš„è¡ç”Ÿç‰©ï¼Œå…·æœ‰å¤šé€šé“é˜»æ–·ä½œç”¨ï¼Œèƒ½ç¶­æŒç«‡æ€§å¿ƒå¾‹ã€‚
å¿ƒæˆ¿çº–ç¶­é¡«å‹•æ˜¯ä¸­é¢¨çš„ä¸»è¦å±éšªå› ç´ ï¼Œé€éç¶­æŒç«‡æ€§å¿ƒå¾‹å¯æ¸›å°‘å¿ƒæˆ¿è¡€æ “å½¢æˆã€‚
ATHENA è©¦é©—çš„äº‹å¾Œåˆ†æé¡¯ç¤º dronedarone å¯é™ä½ä¸­é¢¨å’Œæš«æ™‚æ€§è…¦ç¼ºè¡€ç™¼ä½œé¢¨éšªï¼Œ
ä¸”ç ”ç©¶ç™¼ç¾å…¶å…·æœ‰ç¨ç«‹æ–¼æŠ—å¿ƒå¾‹ä¸æ•´ä½œç”¨ä¹‹å¤–çš„æŠ—å‡è¡€å’ŒæŠ—è¡€å°æ¿æ•ˆæ‡‰ã€‚
</p>

<div class="key-takeaway">
æ­¤é æ¸¬åŸºæ–¼è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰ï¼Œèˆ‡ç¾æœ‰è‡¨åºŠè­‰æ“šæ–¹å‘ä¸€è‡´ã€‚
</div>

### è‡¨åºŠè©¦é©—

| è©¦é©—ç·¨è™Ÿ | éšæ®µ | ç‹€æ…‹ | äººæ•¸ | ä¸»è¦ç™¼ç¾ |
|---------|------|------|------|---------|
| [NCT01151137](https://clinicaltrials.gov/study/NCT01151137) | Phase 3 | TERMINATED | 3236 | PALLAS è©¦é©—è©•ä¼° dronedarone åœ¨æ°¸ä¹…æ€§å¿ƒæˆ¿çº–ç¶­é¡«å‹•é é˜²ä¸»è¦å¿ƒè¡€ç®¡äº‹ä»¶ |
| [NCT01288352](https://clinicaltrials.gov/study/NCT01288352) | Phase 4 | COMPLETED | 2789 | EAST è©¦é©—è­‰å¯¦æ—©æœŸç¯€å¾‹æ§åˆ¶å¯é é˜²å¿ƒè¡€ç®¡æ­»äº¡å’Œä¸­é¢¨ |
| [NCT05130268](https://clinicaltrials.gov/study/NCT05130268) | Phase 4 | COMPLETED | 339 | è©•ä¼°é¦–ç™¼å¿ƒæˆ¿çº–ç¶­é¡«å‹•æ‚£è€…æ—©æœŸä½¿ç”¨ dronedarone çš„æ•ˆæœ |
| [NCT05293080](https://clinicaltrials.gov/study/NCT05293080) | Phase 3 | NOT_YET_RECRUITING | 1746 | æ€¥æ€§ä¸­é¢¨åˆä½µå¿ƒæˆ¿çº–ç¶­é¡«å‹•æ‚£è€…çš„æ—©æœŸç¯€å¾‹æ§åˆ¶ |
| [NCT00911508](https://clinicaltrials.gov/study/NCT00911508) | N/A | COMPLETED | 2204 | CABANA è©¦é©—æ¯”è¼ƒå°ç®¡æ¶ˆèèˆ‡æŠ—å¿ƒå¾‹ä¸æ•´è—¥ç‰©æ²»ç™‚ |

### ç›¸é—œæ–‡ç»

| PMID | å¹´ä»½ | é¡å‹ | æœŸåˆŠ | ä¸»è¦ç™¼ç¾ |
|------|-----|------|------|---------|
| [22166900](https://pubmed.ncbi.nlm.nih.gov/22166900/) | 2012 | Review | Lancet | å¿ƒæˆ¿çº–ç¶­é¡«å‹•æ²»ç™‚é€²å±•ï¼ŒåŒ…æ‹¬ dronedarone çš„è§’è‰² |
| [28992468](https://pubmed.ncbi.nlm.nih.gov/28992468/) | 2017 | In vitro | Atherosclerosis | Dronedarone å…·æœ‰ç¨ç«‹æ–¼æŠ—å¿ƒå¾‹ä¸æ•´ä½œç”¨çš„æŠ—å‡è¡€å’ŒæŠ—è¡€å°æ¿æ•ˆæ‡‰ |
| [40387892](https://pubmed.ncbi.nlm.nih.gov/40387892/) | 2025 | RCT analysis | Clin Res Cardiol | EAST-AFNET 4 è©¦é©—ä¸­ amiodarone å’Œ dronedarone ç”¨æ–¼æ—©æœŸç¯€å¾‹æ§åˆ¶çš„å®‰å…¨æ€§å’Œç™‚æ•ˆ |
| [20730068](https://pubmed.ncbi.nlm.nih.gov/20730068/) | 2010 | Review | Vasc Health Risk Manag | Dronedarone ç²æ‰¹åŠå…¶åœ¨å¿ƒæˆ¿çº–ç¶­é¡«å‹•æ²»ç™‚ä¸­çš„ç™‚æ•ˆ |
| [35293087](https://pubmed.ncbi.nlm.nih.gov/35293087/) | 2022 | Post-hoc analysis | Eur J Heart Fail | ATHENA è©¦é©—äº‹å¾Œåˆ†æè©•ä¼° dronedarone åœ¨ HFpEF/HFmrEF åˆä½µå¿ƒæˆ¿çº–ç¶­é¡«å‹•çš„æ•ˆæœ |

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. obsolete susceptibility to ischemic stroke</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.96%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.96%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. ABri amyloidosis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.92%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.92%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. cerebrovascular disorder</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.71%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.71%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. brain stem infarction</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.71%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.71%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. sick sinus syndrome 2, autosomal dominant</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.63%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.63%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. duodenal obstruction</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.56%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.56%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. cerebral artery occlusion</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.44%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.44%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. sarcoglycanopathy</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.43%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.43%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. Wildervanck syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.37%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.37%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| 1 å¼µè¨±å¯è­‰ | æ±ºå¥ˆé”éš†é¹½é…¸é¹½ | å£æœåŠ‘å‹ | é™£ç™¼æ€§æˆ–æŒçºŒæ€§å¿ƒæˆ¿çº–ç¶­é¡«å‹•/å¿ƒæˆ¿æ’²å‹•ï¼Œé™ä½å¿ƒæˆ¿é¡«å‹•ä½é™¢é¢¨éšª |

## å®‰å…¨æ€§è€ƒé‡

- **é»‘æ¡†è­¦å‘Š**ï¼šæ°¸ä¹…æ€§å¿ƒæˆ¿çº–ç¶­é¡«å‹•ã€åš´é‡å¿ƒè¡°ç«­æ‚£è€…ç¦ç”¨
- **ä¸»è¦ä¸è‰¯åæ‡‰**ï¼šè…¹ç€‰ã€å™å¿ƒã€è…¹ç—›ã€è¡€æ¸…è‚Œé…å‡é«˜
- **è‚æ¯’æ€§**ï¼šç½•è¦‹ä½†åš´é‡ï¼Œéœ€ç›£æ¸¬è‚åŠŸèƒ½
- **è—¥ç‰©äº¤äº’ä½œç”¨**ï¼šèˆ‡ digoxin ä½µç”¨æ™‚æœƒå¢åŠ  digoxin è¡€ä¸­æ¿ƒåº¦

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**è‘¡è„æŸšæ± (grapefruit juice)** ğŸŸ¢ Minor
- å½±éŸ¿ï¼šGrapefruit juice may increase the plasma concentrations of dronedarone.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present ...
- å»ºè­°ï¼šPatients treated with dronedarone should avoid consumption of grapefruit, grapefruit juice, and any supplement containing grapefruit extract.  Dronedarone should be taken twice daily with the morning ...

### è—¥ç‰©-è‰è—¥äº¤äº’ä½œç”¨ (DHI)

**è–ç´„ç¿°è‰ï¼ˆè²«è‘‰é€£ç¿¹ï¼‰** ğŸ”´ Major
- å½±éŸ¿ï¼šè–ç´„ç¿°è‰é™ä½ Dronedarone è¡€ä¸­æ¿ƒåº¦
- å»ºè­°ï¼šç¦æ­¢ä½µç”¨



### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**Cardiomyopathies** ğŸŸ¢ Minor
- Dronedarone has shown to double the risk of death in patients with symptomatic heart failure and recent decompensation requiring hospitalization or NYHA Class IV heart failure.  It has also shown to double the risk of stroke and death and hospitaliza...

**è‚è‡Ÿç–¾ç—… (Liver Diseases)** ğŸŸ¢ Minor
- Dronedarone is extensively metabolized by the liver.  There is little clinical experience with moderate hepatic impairment and none in patients with severe hepatic impairment.  No dosage adjustment is recommended for patients with moderate hepatic im...

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šProceed with Guardrails**

**ç†ç”±ï¼š**
Dronedarone é€éç¶­æŒç«‡æ€§å¿ƒå¾‹å’Œæ½›åœ¨çš„æŠ—è¡€æ “æ©Ÿåˆ¶ï¼Œå¯èƒ½å°ä¸­é¢¨é é˜²æœ‰æ•ˆã€‚
ATHENA è©¦é©—å·²é¡¯ç¤ºå…¶åœ¨ä¸­é¢¨/TIA é é˜²æ–¹é¢çš„ç›Šè™•ï¼Œä½†éœ€æ³¨æ„é©æ‡‰ç—‡é™åˆ¶ã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- æ’é™¤æ°¸ä¹…æ€§å¿ƒæˆ¿çº–ç¶­é¡«å‹•å’Œåš´é‡å¿ƒè¡°ç«­æ‚£è€…
- åš´æ ¼çš„è‚åŠŸèƒ½ç›£æ¸¬è¨ˆç•«
- èˆ‡æŠ—å‡è¡€è—¥ç‰©ä½µç”¨ç­–ç•¥çš„å„ªåŒ–ç ”ç©¶


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Carboplatin]({{ "/drugs/carboplatin/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Hydroxyurea]({{ "/drugs/hydroxyurea/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Hydroxyprogesterone Caproate]({{ "/drugs/hydroxyprogesterone_caproate/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Oteracil]({{ "/drugs/oteracil/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Prednisone]({{ "/drugs/prednisone/" | relative_url }}) - è­‰æ“šç­‰ç´š L2

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Dronedaroneè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/dronedarone/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_dronedarone,
  title = {Dronedaroneè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/dronedarone/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
